AIM ImmunoTech Announces Authorizations From Competent Authority And Ethics Board In The Netherlands To Begin A Phase 1b/2 Study Evaluating Ampligen In Combination With AstraZeneca's Imfinzi For The Treatment Of Pancreatic Can
Portfolio Pulse from Happy Mohamed
AIM ImmunoTech has received approvals from the Netherlands to begin a Phase 1b/2 study evaluating Ampligen in combination with AstraZeneca's Imfinzi for the treatment of pancreatic cancer. Patient enrollment is expected to commence before the end of 2023.
June 27, 2023 | 12:47 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
AIM ImmunoTech received approval to begin a Phase 1b/2 study with AstraZeneca's Imfinzi for pancreatic cancer treatment, potentially increasing survival rates and efficacy.
The approval to begin the Phase 1b/2 study is a significant milestone for AIM ImmunoTech, as it could lead to increased survival rates and efficacy in pancreatic cancer treatment. This positive news is likely to have a short-term positive impact on AIM's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
POSITIVE IMPACT
AstraZeneca's Imfinzi will be evaluated in combination with AIM ImmunoTech's Ampligen in a Phase 1b/2 study for the treatment of pancreatic cancer.
The collaboration with AIM ImmunoTech to evaluate Imfinzi in combination with Ampligen for pancreatic cancer treatment could potentially lead to increased survival rates and efficacy. This positive news is likely to have a short-term positive impact on AstraZeneca's stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80